<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130519</url>
  </required_header>
  <id_info>
    <org_study_id>100114</org_study_id>
    <secondary_id>10-C-0114</secondary_id>
    <nct_id>NCT01130519</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer</brief_title>
  <official_title>A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  At the present time, there are no drugs that have been proven to work in patients with&#xD;
           papillary kidney cancer that has spread (metastasized) beyond the kidneys. Researchers&#xD;
           are interested in determining whether the combination of the drugs bevacizumab and&#xD;
           erlotinib can be used to treat metastatic papillary kidney cancer.&#xD;
&#xD;
        -  Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is an inherited type of&#xD;
           papillary kidney cancer (it runs in families). Papillary kidney cancer can also occur&#xD;
           sporadically, or without a family connection. More research is needed to determine&#xD;
           whether treatments for papillary kidney cancer, such as bevacizumab and erlotinib, work&#xD;
           in inherited or sporadic types of kidney cancer, and if so, whether there are any&#xD;
           differences.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      -To determine the effectiveness of the combination of bevacizumab and erlotinib as a&#xD;
      treatment for patients with (1) metastatic HLRCC kidney cancer and (2) metastatic kidney&#xD;
      cancer not associated with HLRCC (or sporadic papillary RCC).&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Individuals 18 years of age or older who have been diagnosed with papillary kidney&#xD;
           cancer that has spread beyond the kidneys.&#xD;
&#xD;
        -  Participants may have either HLRCC or sporadic papillary kidney cancer.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a full medical history, physical examination, blood&#xD;
           and urine tests, and CT and other scans to evaluate tumor size and treatment options.&#xD;
&#xD;
        -  Participants will receive 28-day treatment cycles of bevacizumab (given intravenously&#xD;
           every 2 weeks) and erlotinib (a tablet taken by mouth daily).&#xD;
&#xD;
        -  Every cycle, participants will return for regular blood and urine tests. Every other&#xD;
           cycle, participants will have imaging scans to assess tumor size and response to&#xD;
           treatment. Female participants who have uterine fibroid tumors related to their kidney&#xD;
           cancer may have additional scans to assess tumor size and response to treatment.&#xD;
&#xD;
        -  Participants will continue to receive treatment on the study until their tumors grow or&#xD;
           spread to new areas (disease progression), intolerable side effects develop, a better&#xD;
           treatment option becomes available, the study closes, it is unsafe to continue&#xD;
           treatment, or the participant decides not to remain in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
        -  Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a familial cancer syndrome&#xD;
           characterized by a propensity for developing renal cancer, and uterine and cutaneous&#xD;
           leiomyomas. The kidney cancer associated with HLRCC is clinically aggressive and is&#xD;
           characterized by unique histopathologic features that are sometimes described as type 2&#xD;
           papillary RCC.&#xD;
&#xD;
        -  Germline mutations in the fumarate hydratase (FH) gene are the genetic hallmark of&#xD;
           HLRCC. Mutational inactivation of FH has been shown to result in VHL-independent&#xD;
           upregulation of hypoxia inducible factor (HIF) and its downstream transcriptional&#xD;
           targets.&#xD;
&#xD;
        -  The recognition that HIF upregulation may play an important role in the formation and&#xD;
           propagation of renal cancer associated with HLRCC suggests that interventions directed&#xD;
           against components of this pathway, such as VEGF and TGF-Alpha/EGFR, may be of benefit&#xD;
           in this patient population.&#xD;
&#xD;
        -  We propose to test the hypothesis that dual VEGF/EGFR blockade with&#xD;
           bevacizumab/erlotinib is likely to be clinically active in patients with HLRCC&#xD;
           associated RCC as well as those with sporadic papillary sporadic RCC.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      Primary Objective&#xD;
&#xD;
      -To determine the overall response rate (RECIST) in patients with 1) metastatic RCC&#xD;
      associated with HLRCC and 2) metastatic sporadic/non-HLRCC papillary renal cancer treated&#xD;
      with a combination of bevacizumab and erlotinib&#xD;
&#xD;
      Eligibility&#xD;
&#xD;
        -  Diagnosis of advanced RCC associated with HLRCC (cohorts 1 and 3) or sporadic/non-HLRCC&#xD;
           papillary RCC (cohorts 2 and 4)&#xD;
&#xD;
        -  ECOG PS 0-2&#xD;
&#xD;
        -  Measurable disease, consistent with RECIST 1.1&#xD;
&#xD;
        -  No history of major bleeding, recent or active myocardial ischemia, GI perforation,&#xD;
           cerebrovascular accidents or other significant intercurrent illness&#xD;
&#xD;
        -  No coagulopathy or bleeding diathesis&#xD;
&#xD;
        -  No recent surgery (&lt; 4 weeks or inadequately healed surgical scars)&#xD;
&#xD;
        -  Adequate organ function&#xD;
&#xD;
        -  Adequate liver function (total bilirubin &lt;= 1.5 mg/dL or &lt; 3 x upper limit of normal&#xD;
           (ULN) in subjects with Gilbert s disease, and AST (SGOT) / ALT (SGPT) 2.5 x ULN&#xD;
&#xD;
        -  Adequate renal function (creatinine &lt;= 2.0 x ULN or creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
        -  Neutrophils &gt;1500/microL and platelets &gt;100,000&#xD;
&#xD;
        -  No brain metastases&#xD;
&#xD;
        -  No more than 2 prior regimens containing a VEGF-pathway inhibitor; no prior therapy with&#xD;
           bevacizumab&#xD;
&#xD;
        -  Ability to understand and sign informed consent&#xD;
&#xD;
      Design&#xD;
&#xD;
        -  Patients will receive a fixed starting dose of bevacizumab (10mg/kg IV every 2 weeks)&#xD;
           and erlotinib (150mg/day po). Dose reductions and drug interruptions for unacceptable&#xD;
           toxicity will be allowed.&#xD;
&#xD;
        -  Patients will be evaluated for response every 8 weeks using RECIST criteria&#xD;
&#xD;
        -  The study is based on an open label Simon two-stage minmax design in two cohorts, 1)&#xD;
           cohort 1- patients with HLRCC, and 2) cohort 2- patients with sporadic papillary RCC. In&#xD;
           each cohort, 13 patients will be accrued in the first stage and will accrue a maximum of&#xD;
           20 patients. Accrual into and analysis of the two cohorts will be independent.&#xD;
&#xD;
        -  Following completion of accrual to cohorts 1 and 2, the study was expanded to include&#xD;
           two additional cohorts- Cohort 3 (HLRCC patients and Cohort 4 (patients with&#xD;
           sporadic/non HLRCC papillary RCC) to better estimate the overall response rate and to&#xD;
           perform additional exploratory biomarker analyses. Up to 20 additional evaluable&#xD;
           patients will be included in each of these cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 6, 2010</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate.</measure>
    <time_frame>4-5 years</time_frame>
    <description>Proportion of patients whose tumors shrunk after therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, duration of response and overall survival</measure>
    <time_frame>4-5 years</time_frame>
    <description>Median amount of time subject survives without disease progression after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>HLRCC</condition>
  <condition>Sporadic Papillary Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patient will be receiving fixed starting dose of bevacizumab (10 mg/kg IV every 2 weeks) and erlotinib (150 mg/day PO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Commercially available. Administered by intravenous infusion.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Commercially available. Administered orally.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Patients must meet all the following criteria to be eligible for study enrolment:&#xD;
&#xD;
          -  Diagnosis of advanced RCC associated with HLRCC (cohorts 1 &amp; 3) or sporadic/non-HLRCC&#xD;
             papillary RCC (cohort 2 &amp; 4)&#xD;
&#xD;
          -  Measurable disease outlined in RECIST 1.1&#xD;
&#xD;
          -  No more than two prior regimens targeting the VEGF pathway; no prior bevacizumab&#xD;
             therapy&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Performance status ECOG 0-2&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below: WBC count&#xD;
             greater than or equal to 3,000/microL, absolute neutrophil count greater than or equal&#xD;
             to 1,500/microL, platelet count greater than or equal to 100,000/microL, serum&#xD;
             creatinine greater than or equal to 2 times the upper limit of reference range or&#xD;
             creatinine clearance greater than or equal to 30 ml/min, AST and ALT less than 2.5&#xD;
             times the upper limit of reference range, total bilirubin less than 1.5 times the&#xD;
             upper limit of reference range ( less than 3 x upper limit of reference range in&#xD;
             patients with Gilbert s disease), alkaline phosphatase less than or equal to 2.5 times&#xD;
             the upper limit of reference range (or less than than or equal to 5 times the upper&#xD;
             limit of reference range if considered to be related to liver or bone metastases by&#xD;
             the PI)&#xD;
&#xD;
          -  Recovery from acute toxicity of prior treatment for RCC (to less than or equal to&#xD;
             grade 1 the active version of CTCAE or to a level permitted under other sections of&#xD;
             Inclusion/ Exclusion criteria).&#xD;
&#xD;
          -  At least 4 weeks from completion of major surgery and a healed surgical incision&#xD;
&#xD;
          -  Negative pregnancy test (within 7 days of enrolment) in women of childbearing&#xD;
             potential&#xD;
&#xD;
          -  No myocardial infarction, GI perforation/fistula, intraabdominal abscess,&#xD;
             cerebrovascular accidents within six months prior to study entry&#xD;
&#xD;
          -  No coagulopathy or bleeding diathesis&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Archival tissue block or unstained tumor tissue available for correlative studies&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Prior invasive malignancy of other histology, with the exception of adequately treated&#xD;
             basal or squamous cell carcinoma of the skin, or any other malignancy for which the&#xD;
             patient does not currently require treatment and/or has no evidence of disease for&#xD;
             greater than or equal to 2 years.&#xD;
&#xD;
          -  Patients with known brain metastases unless treated with an appropriate modality with&#xD;
             no evidence of progression/recurrence for greater than 3 months&#xD;
&#xD;
          -  Hypertension not controlled by medical therapy (resting systolic blood pressure&#xD;
             greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg on at least two&#xD;
             occasions over a 24 hour period despite optimal medical management).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring intravenous antibiotics, symptomatic congestive heart failure (New&#xD;
             York Heart Association grade III or greater), unstable angina pectoris, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Serious, non-healing wound or ulcer; bone fracture within 3 months prior to study&#xD;
             entry&#xD;
&#xD;
          -  Patient known to be HIV-positive and requiring antiretroviral therapy (due to the risk&#xD;
             of potential drug interactions)&#xD;
&#xD;
          -  Concomitant therapy with potent inhibitors of CYP450 3A4 (e.g. ketoconazole, verapamil&#xD;
             etc) or with potent CYP450 1A2 inhibitors (fluoroquinolone antibiotics including&#xD;
             ciprofloxacin, levofloxacin, and norfloxacin; ticlodipine, cimetidine, amiodarone,etc.&#xD;
             see Appendix C)&#xD;
&#xD;
          -  Pregnant women are excluded from this study because bevacizumab and erlotinib are&#xD;
             anti-cancer agents with the potential for teratogenic or abortifacient effects.&#xD;
             Because there is an unknown but potential risk for adverse events in nursing infants&#xD;
             secondary to treatment of the mother with these agents, breastfeeding should be&#xD;
             discontinued if the mother is treated on this study&#xD;
&#xD;
          -  All men and women of childbearing potential must be willing to use effective&#xD;
             contraception as determined by the principal investigator (including but not limited&#xD;
             to abstinence, hormonal contraceptives (birth control pills, injections, or implants),&#xD;
             intrauterine device (IUD), tubal ligation, vasectomy) from the time of enrolment to at&#xD;
             least six months following the last dose of drug&#xD;
&#xD;
          -  Any known hypersensitivity to bevacizumab, erlotinib or other excipients of these&#xD;
             drugs&#xD;
&#xD;
          -  Documented baseline proteinuria greater than 1000mg/day on 24 hour urine collection.&#xD;
             Only patients with 1+ or greater proteinuria on UA and a spot urine protein:creatinine&#xD;
             ratio of greater than 0.5 will undergo a 24 hour urine collection for quantitation of&#xD;
             proteinuria.&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 40% as measured on transthoracic&#xD;
             echocardiogram.&#xD;
&#xD;
        INCLUSION OF WOMEN AND MINORITIES:&#xD;
&#xD;
        Both men and women and members of all races and ethnic groups are eligible for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramaprasad Srinivasan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2010-C-0114.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, Walther MM, Merino MJ, Zbar B, Linehan WM, Toro JR. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006 Jan;43(1):18-27. Epub 2005 Jun 3.</citation>
    <PMID>15937070</PMID>
  </reference>
  <reference>
    <citation>Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, Salovaara R, Herva R, Koivisto PA, Vierimaa O, Aittom√§ki K, Pukkala E, Launonen V, Aaltonen LA. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet. 2006 Jun;43(6):523-6. Epub 2005 Sep 9.</citation>
    <PMID>16155190</PMID>
  </reference>
  <reference>
    <citation>Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007 Oct;31(10):1578-85.</citation>
    <PMID>17895761</PMID>
  </reference>
  <verification_date>September 14, 2021</verification_date>
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Renal Cell Cancer</keyword>
  <keyword>Hereditary Leiomyomatosis and Renal Cell Cancer</keyword>
  <keyword>HLRCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Leiomyomatosis</mesh_term>
    <mesh_term>Neoplastic Syndromes, Hereditary</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

